Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $3.42
Previous CloseN/A
Volume775.41K
Average Volume (3M)556.54K
Market Cap
$28.40M
Enterprise Value-$18.68M
Total Cash (Recent Filing)$238.60M
Total Debt (Recent Filing)$682.00K
Price to Earnings (P/E)―
Beta3.55
Next Earnings
May 06, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding58,415,955
10 Day Avg. Volume542,942
30 Day Avg. Volume556,536
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$5.50Price Target Upside1022.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
BioAtla News
PremiumCompany Announcements
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
PremiumCompany Announcements
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Drug Development And Clinical TrialsThe drug was well-tolerated and demonstrated tumor reduction in multiple patients.
Workforce And Cost ManagementBioAtla has reduced its workforce by over 30%, which increases its cash runway into the first half of 2026.
Bears Say
Financial PerformanceBioAtla reported no revenue and a net loss of $14.9M for the fourth quarter.
Pipeline DevelopmentThere are few meaningful catalysts from the company’s pipeline in the next 12 months, potentially deteriorating its financial strength.
---
Ownership Overview
9.17% Insiders
4.82% Mutual Funds
0.92% Other Institutional Investors
80.49% Public Companies and
Individual Investors
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $3.42 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $28.40M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is May 06, 2025 which is in 5 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Mar 27, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.085.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.29.
How many shares outstanding does BioAtla have?
BioAtla has 58,415,955 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -5.128%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
---
BioAtla Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (1022.45% Upside)
$5.50 (1022.45% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.44%
12-Months-Change
Fundamentals
Return on Equity
-164.30%
Trailing 12-Months
Asset Growth
-56.19%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
---
BCAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in BioAtla's clinical programs, particularly in the areas of CAB platform development and Phase 2 clinical programs, showing promising therapeutic potential and favorable response rates. Financial strategies are in place to ensure sustainability and future growth, although there are concerns regarding decreased cash reserves and workforce reductions. Overall, the positive clinical progress and strategic positioning outweigh the financial lowlights.Read More>---
BCAB Stock 12 Month Forecast
Average Price Target
$5.50
▲(1022.45% Upside)
Technical Analysis
Lisata Therapeutics
―
ProMIS Neurosciences
―
ImmunoPrecise Antibodies
―
Elevation Oncology
―
Jupiter Neurosciences, Inc.
―
---